Institute of Clinical Neuroimmunology, University Hospital, LMU Munich, Munich, Germany.
Biomedical Center (BMC), Faculty of Medicine, LMU Munich, Martinsried, Germany.
Neurotherapeutics. 2022 Apr;19(3):774-784. doi: 10.1007/s13311-022-01214-x. Epub 2022 Mar 14.
Progressive multiple sclerosis (PMS) is clinically distinct from relapsing-remitting MS (RRMS). In PMS, clinical disability progression occurs independently of relapse activity. Furthermore, there is increasing evidence that the pathological mechanisms of PMS and RRMS are different. Current therapeutic options for the treatment of PMS remain inadequate, although ocrelizumab, a B-cell-depleting antibody, is now available as the first approved therapeutic option for primary progressive MS. Recent advances in understanding the pathophysiology of PMS provide hope for new innovative therapeutic options: these include antibody therapies with anti-inflammatory, neuroprotective, and/or remyelination-fostering effects. In this review, we summarize the relevant trial data relating to antibody therapy and consider future antibody options for treating PMS.
进行性多发性硬化症（PMS）在临床上与复发缓解型多发性硬化症（RRMS）不同。在 PMS 中，临床残疾进展与复发活动无关。此外，越来越多的证据表明 PMS 和 RRMS 的病理机制不同。目前治疗 PMS 的治疗方法仍然不足，尽管奥瑞珠单抗，一种 B 细胞耗竭抗体，现在是第一个被批准用于原发性进展型多发性硬化症的治疗方法。对 PMS 病理生理学的理解的最新进展为新的创新治疗方法提供了希望：这些方法包括具有抗炎、神经保护和/或促进髓鞘再生作用的抗体疗法。在这篇综述中，我们总结了与抗体治疗相关的相关试验数据，并考虑了治疗 PMS 的未来抗体选择。
